The internal consistency of PRO fatigue instruments in sarcoidosis: Superiority of the PFI over the fas

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 30, Issue 1, 2013, Pages 60-64

  Kalkanis, A ^a,b   Yucel, R M ^c   Judson, Marc A ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b SISMANOGLIO HOSPITAL   (Greece)

^c UNIVERSITY AT ALBANY   (United States)

Author keywords

Cronbach's alpha; Fatigue; PRO; Sarcoidosis

Indexed keywords

ADULT; ARTICLE; FATIGUE; FATIGUE ASSESSMENT SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT REPORTED OUTCOME QUESTIONNAIRE; PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEMS FATIGUE INSTRUMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RELIABILITY; SARCOIDOSIS;

ADULT; FATIGUE; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SARCOIDOSIS;

EID: 84879348066     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. .Michielsen HJ, Drent M, Peros-Golubicic T, et al. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006; 130: 989-94. (Pubitemid 44583726)
2. De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, et al. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 127-36. (Pubitemid 38954753)
3. .Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38: 628-34.
4. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis- associated fatigue. Chest 2008; 133: 1189-95. (Pubitemid 351685525)
5. Drent M, Verbraecken J, van der Grinten C, et al. Fatigue associated with obstructive sleep apnea in a patient with sarcoidosis. Respiration 2000; 67: 337-40. (Pubitemid 30330432)
6. .Wagner MT, Marion SD, Judson MA.The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 235. (Pubitemid 41668362)
7. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79.
8. Lai JS, Cella D, Choi S, et al. How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. Arch Phys Med Rehabil 2011; 92: S20-27.
9. Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. J Psychosom Res 2003; 54: 345-52. (Pubitemid 38365998)
10. de Kleijn WP, De Vries J, Wijnen PA, et al.Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med 2011; 105: 1388-95.
11. Cook KF, Bamer AM, Roddey TS, et al. A PROMIS fatigue short form for use by individuals who have multiple sclerosis.Qual Life Res 2011.
12. Christodoulou C, Junghaenel DU, DeWalt DA, et al. Cognitive interviewing in the evaluation of fatigue items: results from the patient-reported outcomes measurement information system (PROMIS). Qual Life Res 2008; 17: 1239-46.
13. Hays RD, Bjorner JB, Revicki DA, et al. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res 2009; 18: 873-80.
14. Junghaenel DU, Christodoulou C, Lai JS, et al. Demographic correlates of fatigue in the US general population: results from the patient-reported outcomes measurement information system (PROMIS) initiative. J Psychosom Res 2011; 71: 117-23.
15. DeWalt DA, Rothrock N, Yount S, et al. Evaluation of item candidates: the PROMIS qualitative item review. Med Care 2007; 45: S12-21.
16. Judson MA. The diagnosis of sarcoidosis. Clin Chest Med 2008; 29: 415-427, viii. (Pubitemid 351784487)
17. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-73.
18. Lai JS, Cella D, Chang CH, et al. Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res 2003; 12: 485-501. (Pubitemid 37056041)
19. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 75-86. (Pubitemid 29164274)
20. George D, Mallery P. SPSS for Windows Step by Step: A simple guide and reference. 11.0 update. 4th ed. Boston: Allyn and Bacon, 2003.
21. De Vries J, Michielsen H, Van Heck GL, et al.Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004; 9: 279-91. (Pubitemid 39277403)
22. Hays RD, Revicki D. Reliability and validity (including responsiveness). In: Fayers P, Hays RD, eds. Assessing Quality of Life in Clinical Trials. New York: Oxford University Press, 2005; 25-39.
23. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-9. (Pubitemid 33152325)